Dose-escalation strategies which use subgroup information-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose-escalation strategies which use subgroup information

Published:2018-06-13 Issue: Volume: Page:
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Cotterill Amy¹^ORCID,Jaki Thomas²^ORCID

Affiliation:

1. Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences; University of Birmingham; Birmingham UK

2. Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics; Lancaster University; Lancaster UK

Funder

National Institute for Health Research

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1860/fullpdf

Reference44 articles.

1. Bayesian decision procedures based on logistic regression models for dose-finding studies;Whitehead;J Biopharm Stat,1998

2. Competing designs for phase I clinical trials: a review;Rosenberger;Stat Med,2002

3. KRAS mutation status is predictive of response to Cetuximab therapy in colorectal cancer;Lièvre;Cancer Res,2006

4. Hypothesis testing in a confirmatory phase III trial with a possible subset effect;Chen;Stat Biopharm Res,2009

5. Enrichment designs: Efficiency in development of cancer treatments;Temple;J Clin Oncol,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early phase clinical trials in oncology: Realising the potential of seamless designs;European Journal of Cancer;2023-08

2. Patient-specific dose finding in seamless phase I/II clinical trials;Sequential Analysis;2022-07-03

3. Analyzing adverse drug reaction using statistical and machine learning methods;Medicine;2022-06-24

4. Two‐stage subgroup‐specific time‐to‐event (2S‐Sub‐TITE): An adaptive two‐stage time‐to‐toxicity design for subgroup‐specific dose finding in phase I oncology trials;Pharmaceutical Statistics;2022-05-12

5. Subgroup‐specific dose finding for phase I‐II trials using Bayesian clustering;Statistics in Medicine;2022-04-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3